Clinical usefulness of chemosensitivity test for advanced colorectal cancer

Yasuo Kabeshima, Tetsuro Kubota, Masahiko Watanabe, Hirotoshi Hasegawa, Toshiharu Furukawa, Masaki Kitajima

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We assessed the usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay in the evaluation of appropriate adjuvant cancer chemotherapy for patients with advanced colorectal cancer. We analyzed 405 cases of colorectal cancer treated between January 1990 and August 1999 in terms of the MTT assay and survival outcome. Patients with Dukes' C and D were classified into a "surgery alone" group (n=53), a "sensitive" group who received drugs that had a greater than 50% inhibition rate by MTT assay (n=23), or "resistant"" group who were insensitive to the chemotherapy drugs (n=124). Statistically significant differences in survival outcome were observed between the groups, with the sensitive group showing significantly better survival compared with the resistant group (p=0.0158) and the surgery-alone group (p=0.0004). Our results suggest that the MTT assay may be useful in evaluating the optimum adjuvant chemotherapy for patients with advanced colorectal cancer.

Original languageEnglish
Pages (from-to)3033-3037
Number of pages5
JournalAnticancer Research
Volume22
Issue number5
Publication statusPublished - 2002 Sep

Fingerprint

Colorectal Neoplasms
Adjuvant Chemotherapy
Survival
Pharmaceutical Preparations
Drug Therapy
Neoplasms
thiazolyl blue

Keywords

  • Adjuvant cancer chemotherapy
  • Chemosensitivity
  • Colon carcinoma
  • MTT assay
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kabeshima, Y., Kubota, T., Watanabe, M., Hasegawa, H., Furukawa, T., & Kitajima, M. (2002). Clinical usefulness of chemosensitivity test for advanced colorectal cancer. Anticancer Research, 22(5), 3033-3037.

Clinical usefulness of chemosensitivity test for advanced colorectal cancer. / Kabeshima, Yasuo; Kubota, Tetsuro; Watanabe, Masahiko; Hasegawa, Hirotoshi; Furukawa, Toshiharu; Kitajima, Masaki.

In: Anticancer Research, Vol. 22, No. 5, 09.2002, p. 3033-3037.

Research output: Contribution to journalArticle

Kabeshima, Y, Kubota, T, Watanabe, M, Hasegawa, H, Furukawa, T & Kitajima, M 2002, 'Clinical usefulness of chemosensitivity test for advanced colorectal cancer', Anticancer Research, vol. 22, no. 5, pp. 3033-3037.
Kabeshima Y, Kubota T, Watanabe M, Hasegawa H, Furukawa T, Kitajima M. Clinical usefulness of chemosensitivity test for advanced colorectal cancer. Anticancer Research. 2002 Sep;22(5):3033-3037.
Kabeshima, Yasuo ; Kubota, Tetsuro ; Watanabe, Masahiko ; Hasegawa, Hirotoshi ; Furukawa, Toshiharu ; Kitajima, Masaki. / Clinical usefulness of chemosensitivity test for advanced colorectal cancer. In: Anticancer Research. 2002 ; Vol. 22, No. 5. pp. 3033-3037.
@article{72d963a1795745c4b155530420cdcfbd,
title = "Clinical usefulness of chemosensitivity test for advanced colorectal cancer",
abstract = "We assessed the usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay in the evaluation of appropriate adjuvant cancer chemotherapy for patients with advanced colorectal cancer. We analyzed 405 cases of colorectal cancer treated between January 1990 and August 1999 in terms of the MTT assay and survival outcome. Patients with Dukes' C and D were classified into a {"}surgery alone{"} group (n=53), a {"}sensitive{"} group who received drugs that had a greater than 50{\%} inhibition rate by MTT assay (n=23), or {"}resistant{"}{"} group who were insensitive to the chemotherapy drugs (n=124). Statistically significant differences in survival outcome were observed between the groups, with the sensitive group showing significantly better survival compared with the resistant group (p=0.0158) and the surgery-alone group (p=0.0004). Our results suggest that the MTT assay may be useful in evaluating the optimum adjuvant chemotherapy for patients with advanced colorectal cancer.",
keywords = "Adjuvant cancer chemotherapy, Chemosensitivity, Colon carcinoma, MTT assay, Survival",
author = "Yasuo Kabeshima and Tetsuro Kubota and Masahiko Watanabe and Hirotoshi Hasegawa and Toshiharu Furukawa and Masaki Kitajima",
year = "2002",
month = "9",
language = "English",
volume = "22",
pages = "3033--3037",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Clinical usefulness of chemosensitivity test for advanced colorectal cancer

AU - Kabeshima, Yasuo

AU - Kubota, Tetsuro

AU - Watanabe, Masahiko

AU - Hasegawa, Hirotoshi

AU - Furukawa, Toshiharu

AU - Kitajima, Masaki

PY - 2002/9

Y1 - 2002/9

N2 - We assessed the usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay in the evaluation of appropriate adjuvant cancer chemotherapy for patients with advanced colorectal cancer. We analyzed 405 cases of colorectal cancer treated between January 1990 and August 1999 in terms of the MTT assay and survival outcome. Patients with Dukes' C and D were classified into a "surgery alone" group (n=53), a "sensitive" group who received drugs that had a greater than 50% inhibition rate by MTT assay (n=23), or "resistant"" group who were insensitive to the chemotherapy drugs (n=124). Statistically significant differences in survival outcome were observed between the groups, with the sensitive group showing significantly better survival compared with the resistant group (p=0.0158) and the surgery-alone group (p=0.0004). Our results suggest that the MTT assay may be useful in evaluating the optimum adjuvant chemotherapy for patients with advanced colorectal cancer.

AB - We assessed the usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay in the evaluation of appropriate adjuvant cancer chemotherapy for patients with advanced colorectal cancer. We analyzed 405 cases of colorectal cancer treated between January 1990 and August 1999 in terms of the MTT assay and survival outcome. Patients with Dukes' C and D were classified into a "surgery alone" group (n=53), a "sensitive" group who received drugs that had a greater than 50% inhibition rate by MTT assay (n=23), or "resistant"" group who were insensitive to the chemotherapy drugs (n=124). Statistically significant differences in survival outcome were observed between the groups, with the sensitive group showing significantly better survival compared with the resistant group (p=0.0158) and the surgery-alone group (p=0.0004). Our results suggest that the MTT assay may be useful in evaluating the optimum adjuvant chemotherapy for patients with advanced colorectal cancer.

KW - Adjuvant cancer chemotherapy

KW - Chemosensitivity

KW - Colon carcinoma

KW - MTT assay

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0036765459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036765459&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 3033

EP - 3037

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -